Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?

Cardinal Health (CAH) is anticipated to report robust fiscal Q4 2025 results on August 12, with consensus estimates projecting a 1.3% year-over-year revenue increase to $60.67 billion and a 10.3% rise in EPS to $2.03. This expected performance is driven by continued momentum in the Pharmaceutical segment, a sustained recovery in Medical, and operational efficiencies, building on a consistent trend of earnings beats. CAH shares have significantly outperformed peers and broader market indices year-to-date, reflecting investor confidence in its strategic initiatives, including new distribution centers, despite prevailing macroeconomic uncertainties.

Analysis

Cardinal Health is poised to report its fourth-quarter fiscal 2025 results with consensus estimates projecting a 1.3% year-over-year revenue increase to $60.67 billion and a 10.3% rise in adjusted EPS to $2.03. This anticipated growth is underpinned by sustained momentum in its Pharmaceutical segment, driven by strong branded drug volumes and specialty practice expansion, alongside a continued recovery in the Medical segment supported by improved supply chain execution and demand for at-home solutions. The company's consistent performance, having surpassed EPS estimates in the last four trailing quarters with an average surprise of 10.3%, provides a strong historical precedent. This operational strength is reflected in its stock performance, which has gained 29.7% year-to-date, significantly outperforming its peers, the broader medical sector, and the S&P 500. While its valuation at a 16.5x forward P/E represents a premium to the industry, it remains at a discount to its peer McKesson. Despite the positive outlook and a maintained full-year EPS guidance of $7.20-$7.35, the company's neutral Earnings ESP of 0.00% suggests an earnings beat is not a certainty, and potential risks from macroeconomic instability remain a factor.

Key Decisions for Investors

• Given the stock's substantial 29.7% year-to-date rally and premium valuation, investors should be aware that high expectations are likely priced in, potentially limiting further upside and increasing sensitivity to any negative surprises in the earnings report.
• Investors should closely monitor the performance of the Medical segment and any updates to the full-year guidance, as these will be critical catalysts for justifying the stock's current valuation and sustaining its momentum.
• While the company's long-term strategic investments in automated distribution centers present a compelling growth narrative, the neutral 0.00% Earnings ESP suggests a prudent approach, as an in-line report, rather than a significant beat, is a distinct possibility.